218 search results
- Current search:
- Developmental, psychosocial & learning problems
- Reset
Primary tabs
- Cochrane Evidence (active tab)
- Resources
- Handbooks & Manuals
- Training & Workshops
- News
- All Cochrane sites
-
NewCochrane EvidencePublished 12 Jul 2017
Medications for daytime sleepiness in individuals with idiopathic hypersomnia
Protocol: To assess the effects of medications for daytime sleepiness and related symptoms in individuals with idiopathic hypersomnia, and in particular whether medications may: reduce subjective measures of sleepiness; reduce objective measures of sleepiness; reduce symptoms of cognitive dysfunction; improve quality of life; and be associated ... -
Cochrane EvidencePublished 4 Jul 2017
Splinting for the non-operative management of developmental dysplasia of the hip (DDH) in children under six months of age
Protocol: To determine the role of splinting and the optimal treatment strategy for the non-operative management of DDH in children under six months of age. To identify if there are particular subgroups of patients for whom the optimal management strategy may differ. -
NewCochrane EvidencePublished 11 Jun 2017
Exercise interventions for improving activity, participation and quality of life in people with cerebral palsy
Review question Does exercise improve activity, participation in life situations and quality of life in people with cerebral palsy (CP)? Background Cerebral palsy (CP) is caused by an injury to an infant's brain that interrupts normal development. People with CP have reduced muscle strength and aerobic fitness, which may impact their ability to ... -
Cochrane EvidencePublished 16 May 2017
Family therapy for autism spectrum disorders
Review question What is the evidence that family therapy can help to improve communication, strengthen relationships, and enhance coping, mental health and well-being for people who have autism spectrum disorders (ASDs) or their family members, or both? Background People with ASD often experience difficulty with knowing how to communicate with others, ... -
Cochrane EvidencePublished 2 May 2017
Provision of folic acid for reducing arsenic toxicity in arsenic-exposed children and adults
Protocol: To assess the effects of the provision of folic acid (through folic acid fortified foods or supplements), alone or in combination with other nutrients, on arsenic toxicity and arsenic-related health outcomes (i.e. neurocognitive function, skin lesions, congenital disorders and cancer) in arsenic-exposed populations. -
Cochrane EvidencePublished 29 Mar 2017
Lipid-based nutrient supplements for pregnant women and their impact on pregnancy, birth, and infant developmental outcomes in stable and emergency settings
Protocol: To review the effects of lipid-based nutrient supplements (LNS) when given to women during pregnancy, and their impact on maternal, birth and infant outcomes. To explore the most appropriate composition, frequency and duration of LNS. -
Cochrane EvidencePublished 29 Mar 2017
Provision of preventive lipid-based nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes
Protocol: To assess the effects and safety of preventive lipid-based nutrient supplements (LNS) given with complementary foods on health, nutrition and developmental outcomes of non-hospitalised infants and children 6 to 23 months of age, and whether or not they are more effective than other foods. This review will not assess the effects of ... -
Cochrane EvidencePublished 23 Mar 2017
Dietary interventions for recurrent abdominal pain in children
Review question We reviewed the evidence on the effects of dietary interventions on pain in children aged between five and 18 years with recurrent abdominal pain (RAP). Background Recurrent abdominal pain, or RAP, is a term used for unexplained episodes of stomachache or abdominal pain in children. Recurrent abdominal pain is a common condition, ... -
Cochrane EvidencePublished 15 Mar 2017
Screening tests for Down’s syndrome in the first 24 weeks of pregnancy
Background Down's syndrome (also known as Down's or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental health problems, and disabilities. However, there is wide variation in how Down's affects people. Some individuals are severely affected whilst others have mild problems and are able to lead relatively normal ... -
Cochrane EvidencePublished 15 Mar 2017
Screening tests for Down’s syndrome in first 24 weeks of pregnancy
Background Down's syndrome (also known as Down's or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental health problems, and disabilities. However, there is wide variation in how Down's affects people. Some individuals are severely affected whilst others have mild problems and are able to lead relatively normal ...
